RxDoctor Payments Data

David Coughlin, MD

Neurology · San Diego, CANPI 1740543784

Payments from drug & device makers

$409,615in general payments, 2019–2025

Across 51 payments — averaging $8031.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$389K
  • Medtronic$19K
  • Boston Scientific$871
  • Abbott$241
  • Acadia Pharmaceuticals Inc$127
  • GE HealthCare$115
  • plus $382 from 10 others

What the payments were for

  • Consulting fees$5633%
  • Grants$18,75092%
  • Food & beverage$1,1736%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$409,615 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$161,677
Medicare patients
177
Services billed
14,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa67$117,708
IngrezzaValbenazine Tosylate16$114,802
NuplazidPimavanserin Tartrate13$101,815
GocovriAmantadine Hcl12$41,106
Rasagiline Mesylate37$8,451
Carbidopa-LevodopaCarbidopa/Levodopa159$7,187
Carbidopa-Levodopa ErCarbidopa/Levodopa50$4,089
Gabapentin34$939
AmantadineAmantadine Hcl27$774
Donepezil Hcl22$480
Quetiapine Fumarate19$357
Propranolol Hcl14$353
Pramipexole DihydrochloridePramipexole Di-Hcl12$333
Trazodone Hcl25$274
Clonazepam31$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$36$114,80216 claims
Acadia Pharmaceuticals IncNuplazid$127$101,81513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.

Other neurology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →